MP11-15 THE EFFECT OF A REDUCED DOSE OF APALUTAMIDE ON SKIN-RELATED ADVERSE EVENTS IN ADVANCED PROSTATE CANCER: A MULTICENTER RETROSPECTIVE STUDY

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP11-15 THE EFFECT OF A REDUCED DOSE OF APALUTAMIDE ON SKIN-RELATED ADVERSE EVENTS IN ADVANCED PROSTATE CANCER: A MULTICENTER RETROSPECTIVE STUDY Kyo Togashi, Mutsu, Japan Shingo Hatakeyama, Ryuji Tabata, Daiji Fujimori, Yohei Kawashima, Toshikazu Tanaka, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto Hashimoto, Satoshi Sato, and Chikara Ohyama Kyo TogashiKyo Togashi More articles by this author , Mutsu, Japan Shingo HatakeyamaMutsu, Japan Shingo Hatakeyama More articles by this author , Ryuji TabataRyuji Tabata More articles by this author , Daiji FujimoriDaiji Fujimori More articles by this author , Yohei KawashimaYohei Kawashima More articles by this author , Toshikazu TanakaToshikazu Tanaka More articles by this author , Teppei OkamotoTeppei Okamoto More articles by this author , Hayato YamamotoHayato Yamamoto More articles by this author , Takahiro YoneyamaTakahiro Yoneyama More articles by this author , Yasuhiro Hashimoto HashimotoYasuhiro Hashimoto Hashimoto More articles by this author , Satoshi SatoSatoshi Sato More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003226.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We aimed to evaluate the effect of apalutamide dose reduction on skin-related adverse events (AEs) and castration-resistant prostate cancer (CRPC)-free survival in patients with advanced prostate cancer (PC). METHODS: We retrospectively evaluated 35 patients with nonmetastatic CRPC and 72 treatment-naïve metastatic castration-sensitive PC (mCSPC) patients treated with apalutamide. The primary outcome was the effect of apalutamide dose reduction on skin AEs. The secondary outcomes were the effect of apalutamide dose reduction on skin AEs in patients with small body size, post-skin AE discontinuation rate, and the effect of apalutamide dose reduction on CRPC-free survival in patients with mCSPC treated with upfront apalutamide plus androgen deprivation therapy. RESULTS: Of the 107 patients, 65 (60.7%) and 42 (39.3%) were treated with full and reduced doses of apalutamide, respectively. The skin AE rate was not significantly different between the groups (55% vs. 43%, p=0.761). The incidence rate of skin AEs in the reduced dose of apalutamide was significantly lower in patients with small body size (body weight <67 kg and body mass index <24 kg/m2) than in those with other body sizes. The apalutamide discontinuation rate after skin AEs significantly differed between the full dose (50%) and reduced dose (16.7%) groups. Of the 72 patients with mCSPC, the CRPC-free survival was not significantly different between the full dose and reduced dose groups. CONCLUSIONS: Apalutamide dose reduction was not significantly associated with the incidence of skin AEs. However, dose reduction for patients with small body size may alleviate skin AEs without sacrificing oncological outcome. Source of Funding: nothing © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e130 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kyo Togashi More articles by this author Mutsu, Japan Shingo Hatakeyama More articles by this author Ryuji Tabata More articles by this author Daiji Fujimori More articles by this author Yohei Kawashima More articles by this author Toshikazu Tanaka More articles by this author Teppei Okamoto More articles by this author Hayato Yamamoto More articles by this author Takahiro Yoneyama More articles by this author Yasuhiro Hashimoto Hashimoto More articles by this author Satoshi Sato More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement PDF downloadLoading ...